Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07134205 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer

Name: The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer — clinical trial record (NCT07134205)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 3

SponsorShanghai JMT-Bio Inc.

Started2025-10-01

View on ClinicalTrials.gov ↗

Shanghai JMT-Bio Inc.

31 trials monitored

See all monitored trials

Colorectal Cancer

2,904 trials monitored

See 127 trials at risk

This is a randomized, open-label, multicenter, phase III clinical study. The aim is to evaluate the efficacy of JMT101 in combination with irinotecan in the third-line and beyond treatment of Metastatic Colorectal Cancer.

Trial Details

NCT Number	NCT07134205
Lead Sponsor	Shanghai JMT-Bio Inc.
Conditions	Metastatic Colorectal Cancer (mCRC)
Enrollment	252 participants
Start Date	2025-10-01
Primary Completion	2027-06-01 (estimated)
Study Completion	2028-10-01 (estimated)
Updated on ClinicalTrials.gov	2025-08-21